NHC director receives 7,500-share option grant
National Healthcare Corp director David R. Gifford received a new stock option grant.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
National Healthcare Corp director David R. Gifford received a new stock option grant. He was granted options to purchase 7,500 shares of NHC common stock at an exercise price of $171.42 per share. The options were granted under the 2020 Omnibus Equity Incentive Plan and are scheduled to expire on May 6, 2030. The grant is reported as a compensation-related award and is exempt from Section 16(b) under Rule 16b-3(d).
Insider Trade Summary
Grant/Award: 7,500 shares
Grant/Award
1 txn
Insider
Gifford David R.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock [2026 Grant] | 7,500 | $0.00 | $0.00 |
Holdings After Transaction:
Option to Purchase Common Stock [2026 Grant] — 7,500 contracts (Direct)
Footnotes (1)
- F1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).
Key Figures
Option grant size: 7,500 shares
Exercise price: $171.42 per share
Expiration date: May 6, 2030
+1 more
4 metrics
Option grant size
7,500 shares
Options to purchase common stock granted to director
Exercise price
$171.42 per share
Stock option exercise price for the 2026 grant
Expiration date
May 6, 2030
Stock option expiration for the 2026 grant
Options held after grant
7,500 options
Total derivative securities following transaction
Key Terms
2020 Omnibus Equity Incentive Plan, stock options, Section 16(b), Rule 16b-3(d)
4 terms
2020 Omnibus Equity Incentive Plan financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026."
stock options financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Section 16(b) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d)."
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-3(d) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d)."
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did National Healthcare Corp (NHC) director David R. Gifford report on this Form 4?
David R. Gifford reported receiving a grant of stock options to buy 7,500 shares of National Healthcare Corp common stock. The options were awarded as compensation and reported as a derivative acquisition rather than an open-market purchase or sale.
What is the exercise price and expiration date of David R. Gifford’s NHC stock options?
The options have an exercise price of $171.42 per share and are scheduled to expire on May 6, 2030. This means he can choose to buy NHC shares at $171.42 any time before that expiration date, subject to plan and grant conditions.
Was David R. Gifford’s NHC stock option grant an open-market transaction?
No. The filing shows the transaction code "A," indicating a grant or award rather than an open-market trade. The options were granted under the company’s 2020 Omnibus Equity Incentive Plan as part of compensation, with no purchase price paid at grant.
How many stock options does David R. Gifford hold in NHC after this grant?
After this grant, David R. Gifford is shown holding 7,500 stock options. The filing lists the total derivative securities following the transaction as 7,500, indicating this grant establishes or updates his option position reported in this document.
Why is the NHC stock option grant to David R. Gifford exempt under Section 16(b)?
The footnote states the stock options were granted under the 2020 Omnibus Equity Incentive Plan and are exempt from Section 16(b) pursuant to Rule 16b-3(d). This rule generally provides an exemption for certain board-approved, issuer-granted equity awards to insiders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
